Loading organizations...
PatenSee develops a contactless surveillance system for hemodialysis patients, focusing on early detection of asymptomatic vascular stenosis. This medical device company provides non-contact monitoring to proactively identify vascular access complications, significantly enhancing patient safety and improving long-term outcomes.
Established in 2019 in Or Yehuda, Israel, PatenSee was founded on the insight that continuous, non-invasive monitoring could fundamentally improve care for dialysis patients. The company recognized a critical unmet need for early intervention in vascular access management, moving beyond reactive clinical approaches.
PatenSee's product directly benefits hemodialysis patients by offering enhanced clinical surveillance capabilities. The company’s vision is to set a new standard in safeguarding patient lifelines through advanced vascular access management. It aims to elevate patient care and clinical outcomes with consistent, proactive monitoring.
PatenSee has raised $2.0M across 1 funding round.
PatenSee has raised $2.0M in total across 1 funding round.
PatenSee has raised $2.0M in total across 1 funding round.
PatenSee's investors include 50 Partners, Bain Capital Ventures, Oak HC/FT, Red Cedar Ventures.
PatenSee has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2025 | $2M Seed | — | 50 Partners, Bain Capital Ventures, OAK HC/FT, RED Cedar Ventures | Announced |
PatenSee is a clinical-stage MedTech company building a non-contact, AI-driven optical monitoring system to detect vascular access stenosis early in hemodialysis patients, with the goal of improving outcomes and reducing clinic burden while moving toward commercial launch after clinical trials and regulatory clearance[1][2].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick reminder: The PatenSee system is investigational and not yet FDA‑approved for sale in the U.S.; current information is drawn from company materials, press releases and regulatory announcements cited above[5][1][3].